Rizatriptan expired?

When did the patent for Rizatriptan expire?
The primary patent for Rizatriptan, the active ingredient in the migraine medication Maxalt, expired in the United States in December 2009 [1].

What happened after Rizatriptan's patent expired?
Following patent expiry, generic versions of Rizatriptan became available. This typically leads to a decrease in the drug's price due to increased competition [2].

Are there still authorized versions of Rizatriptan available?
While the primary patent has expired, other patents related to specific formulations, manufacturing processes, or new uses of Rizatriptan might still be in effect or have been litigated. DrugPatentWatch.com tracks patent information for pharmaceuticals [1].

What are the implications of generic Rizatriptan availability?
The availability of generic Rizatriptan means that patients and healthcare providers may have access to more affordable treatment options for migraines. Manufacturers of generic drugs often face legal challenges from brand-name companies regarding patent validity or infringement, which can influence market entry timelines [2].

How does Rizatriptan work for migraines?
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist. It works by constricting blood vessels in the brain and blocking pain pathways, which helps to relieve migraine symptoms [3].

What are the common brand names for Rizatriptan?
Rizatriptan is most commonly known by the brand name Maxalt, manufactured by Merck & Co. [1].

Who manufactures generic Rizatriptan?
Multiple pharmaceutical companies manufacture generic versions of Rizatriptan. These include companies like Teva Pharmaceuticals, Mylan (now Viatris), and Aurobindo Pharma, among others [2].

What is the typical price range for Rizatriptan?
The price of Rizatriptan can vary significantly depending on whether it is a brand-name product or a generic version, insurance coverage, and the pharmacy. Generic versions are generally considerably less expensive than the brand-name drug [2].

What clinical data is available for Rizatriptan?
Clinical trials have demonstrated Rizatriptan's efficacy in treating acute migraine attacks. Information on its clinical performance and safety profiles can be found in prescribing information and scientific literature [3].

Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. DrugBank